California Opens Rulemaking After Estimating Lab Shopping in Nearly a Quarter of Cannabis Tests

California has turned a long-running testing complaint into a quantified enforcement problem

California’s cannabis regulator has put a hard number on a problem the legal market has argued about for years. In a June 5 rulemaking package, the Department of Cannabis Control said a standardized impact analysis estimated that lab shopping accounted for a mean 23.3% of cannabis testing in the state in 2024.

That is the news. Not the suspicion, not the trade gossip, not the accusation from one operator about another. California now has an official estimate saying that nearly one in four tests may have been affected by efforts to secure a more favorable lab result. Even the agency’s lower bound, 19.1%, points to a problem that is not marginal. Its upper bound, 30.3%, suggests the issue could be larger still.

The timing matters because the state has moved from diagnosis to rulemaking. The public comment period on the package runs through July 20, and the proposal would directly change how cannabis transfers are created and approved, how testing samples are moved to laboratories, how retailers fill out certain tax fields in the state system, and whether consumers can obtain certificates of analysis on request. A certificate of analysis is the lab report that shows potency and contaminant results for a product batch.

For California, this is bigger than one more compliance update. The state is using a quantified estimate to justify tighter controls inside its track-and-trace system, the software record that follows legal cannabis as it moves through the licensed market. That turns lab shopping from a credibility complaint into a formally recognized market integrity issue.

The weakness sits in chain of custody, not only in lab science

Lab shopping sounds like a narrow scientific problem, but California’s own explanation places it inside the movement of goods and data. The Initial Statement of Reasons says current workflows can allow multiple samples to be taken from the same batch, incomplete or misleading transfer records, optional use of certain tax fields, and uneven access to certificates of analysis. In plain terms, the state believes too many parts of the record trail can be bent before a consumer ever sees a package on a shelf.

That matters because legal cannabis testing is only as trustworthy as the chain of custody around the sample. A laboratory can test only what it receives. If a distributor or seller can send multiple samples from the same batch, choose among labs, or exploit weak transfer logging, the final number on the package may reflect selection rather than a clean measurement of the batch sold into the market.

In practice, lab shopping usually means a seller or intermediary keeps looking for a better answer. That better answer may be a higher THC result, which can help product marketing and pricing, or a passing result on a contaminant screen that might otherwise block the batch from sale. California’s impact analysis says the behavior is significant enough to distort competition. Honest labs can lose business if they report tougher or less flattering results, while businesses that rely on more favorable testing can gain shelf appeal and revenue.

This is why the June 5 package is built around track-and-trace updates rather than a simple laboratory rule. California’s system, often referred to as CCTT, is the state’s official record of cannabis inventory and movement. The proposal treats lab shopping as a workflow failure as much as a testing failure. If the transfer record is too loose, the sample record can become too loose. If the sample record is too loose, the certificate at the end of the process becomes less credible.

The proposed changes are aimed at that gap. The department says it wants clearer transfer approvals, tighter controls on how samples move from distributors to labs, mandatory use of certain tax-related fields in the system, and a more consistent path for consumers to get certificates of analysis. Read together, those changes are not separate housekeeping items. They are an attempt to make the state record harder to manipulate and easier to audit.

That is an important distinction. California is not merely saying some labs may have performed badly. It is saying the market structure itself can reward favorable answers unless the state makes it harder to shop around, harder to hide the path a sample took, and easier to compare what was tested with what was ultimately sold.

Distributors, labs, retailers and brands would all feel the change differently

The most immediate operational pressure would fall on distributors and testing laboratories, because they sit at the handoff point that the state is trying to tighten. California’s proposal would change how distributors initiate and document transfers and how samples are routed to labs. That means more discipline around timing, record completion, and approval inside the state system. For businesses that already run clean chains of custody, this may look like more paperwork. For businesses that benefited from informal workarounds, it could remove a commercial advantage.

Laboratories would also face a different business environment. If the state narrows the room for sellers to compare labs or run repeated attempts at a favorable outcome, some labs may lose volume that came from permissive sampling relationships rather than superior service. Others may gain if buyers start valuing credibility and consistency more than headline potency. California’s impact analysis matters here because it gives regulators a quantified basis for saying the existing market may reward the wrong kind of lab behavior.

Brands, cultivators, and manufacturers would not be outside the blast radius. Much of cannabis retail still leans heavily on THC numbers as a simple selling tool. If tighter controls reduce potency inflation, some products could come to market with less flattering labels than they might have received under looser testing practices. That does not automatically reduce underlying quality, but it can change how products compete in a market that often treats higher THC as shorthand for value.

Retailers are affected in two distinct ways. First, the proposal would require entry of tax-related fields in the track-and-trace system rather than leaving them as looser or optional data points. That is administrative work, but it also gives the state a fuller record of the transaction chain. Second, retailers could have a clearer obligation to provide certificates of analysis to consumers on request. In practical terms, stores may need better document handling and faster retrieval of batch-level test reports.

Consumers stand to gain more access to testing information, but the benefit is narrower than it may sound. Easier access to a certificate helps only if the underlying test is reliable and tied cleanly to the product sold. California’s rulemaking is trying to strengthen both parts at once: the availability of the report and the integrity of the process that produced it.

For investors and policy watchers, the broader signal is that California has crossed an institutional threshold. The largest legal cannabis market in the United States is no longer speaking about testing integrity in general terms. It is attaching a percentage estimate to the problem and using that estimate to justify intervention in operational plumbing. That matters because valuation, margin analysis, and market-share assumptions all look different when a regulator suggests part of the market may have been competing on distorted test results.

The effect could be uneven. Businesses that built compliance systems for a stricter market may look stronger if the rules land close to the proposal. Businesses that depended on speed, aggressive THC positioning, or flexible sampling arrangements may find that some of their commercial edge was not durable after all.

California’s real test is whether the rule changes behavior rather than simply adding fields

The hard part begins after the comment window closes. California can write tighter rules, but the market outcome depends on whether the state can turn those rules into a cleaner chain of custody in daily operations. That requires software logic that closes loopholes, inspections that compare records against real product movement, and enforcement that reaches beyond obvious paperwork errors.

There is also room for dispute before adoption. Laboratories and operators may challenge the department’s assumptions, the estimated scale of lab shopping, the cost of new workflow controls, or the details of how transfers and samples must be handled. Some will argue that extra process can slow commerce in a market that is already burdened by taxes, price compression, and illicit competition. That argument will matter politically, but it does not erase the core fact now sitting in the rulemaking file: California’s own analysis says the existing system has tolerated a material level of testing distortion.

The deeper issue is trust. Legal cannabis has spent years asking consumers, local officials, and capital providers to treat regulated product as measurably safer and more accountable than the illicit alternative. That case weakens when the state itself concludes that favorable test shopping may have touched roughly a quarter of testing activity. Once that figure enters the record, the debate is no longer about whether a few bad actors exist. It is about whether the legal market’s verification system has been sturdy enough to support the claims made on the label.

That is why this rulemaking matters beyond California’s borders. Other states have struggled with similar complaints about potency inflation, inconsistent laboratory results, and chain-of-custody weaknesses. California has now supplied something more durable than anecdote: a formal estimate, a market rationale, and a proposed set of system controls tied directly to the problem. Regulators elsewhere will notice that.

The market should notice something else. When a regulator quantifies integrity failure, the cost does not disappear. It is either absorbed through tighter processes now or paid later through weaker consumer trust, harsher enforcement, and a deeper discount on anything the system certifies. California has chosen the first route, at least on paper. The next question is whether the state is prepared to force the market to live by it.